Cipla Q4 Results: Net profit jumps 79% YoY to Rs 939 crore on strong sales momentum

Cipla's North America sales, which constitute primarily US, grew 11.8% YoY to Rs 1875 crore driven by key products Lanreotide (used for treating growth hormone disorder) gaining market share to 20.8% and 12-13% Albuterol (anti-asthma inhalation) coupled with robust demand in base business.